Parathyroid adenoma epidemiology and demographics

Jump to navigation Jump to search

Parathyroid adenoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Parathyroid Adenoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Parathyroid adenoma epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Parathyroid adenoma epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Parathyroid adenoma epidemiology and demographics

CDC on Parathyroid adenoma epidemiology and demographics

Parathyroid adenoma epidemiology and demographics in the news

Blogs on Parathyroid adenoma epidemiology and demographics

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Parathyroid adenoma epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

A single parathyroid adenoma is responsible for 80% to 85% of hyperparathyroidism[1]. A double adenomas the culprit in 4% to 5%, and parathyroid hyperplasia in 10% to 12%[2]. Parathyroid carcinomas are very rare causes of hyperparathyroidism and account for less than 1% of disease. Adenomas are most common in patients 50 to 70 years old.They can occur at any age. Women are affected 3-times as often as men

Epidemiology and Demographics

  • A single parathyroid adenoma is responsible for 80% to 85% of hyperparathyroidism[1].
  • A double adenomas the culprit in 4% to 5%, and parathyroid hyperplasia in 10% to 12%[2].
  • Parathyroid carcinomas are very rare causes of hyperparathyroidism and account for less than 1% of disease.
  • Adenomas are most common in patients 50 to 70 years old.
  • They can occur at any age. Women are affected 3-times as often as men.

Prevalence

  • Medulloblastoma is the second most common brain tumor among the pediatric population.[3]
  • Medulloblastoma is considered a rare tumor among adults, as it comprises fewer than 2% of all brain tumors among that age group.

Incidence

  • The overall age adjusted incidence rate of medulloblastoma is approximately 0.71 per 100,000 individuals in the United States.[4]

Age

  • The incidence of medulloblastoma decreases with age; the median age at diagnosis is between 5 to 7 years.[5]
  • The molecular subgroup of medulloblastoma has an influence on the age of presentation such as:[6]
  • WNT medulloblastoma subgroup presents among older children
  • SHH medulloblastoma subgroup presents among infants and adults
  • Group 3 medulloblastoma presents among younger children
  • Group 4 medulloblastoma presents among younger children

Gender

  • The overall age adjusted incidence rate of medulloblastoma among males is approximately 0.84 per 100,000 individuals in the United States.[4]
  • The overall age adjusted incidence rate of medulloblastoma among females is approximately 0.58 per 100,000 individuals in the United States.
  • Males are more commonly affected with medulloblastoma than females. The male to female ratio is approximately 1.44 to 1.

Race

  • There is no racial predilection to medulloblastoma.[7]

References

  1. 1.0 1.1 Edafe O, Collins EE, Ubhi CS, Balasubramanian SP (February 2018). "Current predictive models do not accurately differentiate between single and multi gland disease in primary hyperparathyroidism: a retrospective cohort study of two endocrine surgery units". Ann R Coll Surg Engl. 100 (2): 140–145. doi:10.1308/rcsann.2017.0112. PMC 5838681. PMID 29022783.
  2. 2.0 2.1 Wolfe SA, Sharma S. PMID 29939647. Missing or empty |title= (help)
  3. Medulloblastoma. Wikipedia(2015) https://en.wikipedia.org/wiki/Medulloblastoma Accessed on September, 28th 2015
  4. 4.0 4.1 McKean-Cowdin R, Razavi P, Barrington-Trimis J, Baldwin RT, Asgharzadeh S, Cockburn M; et al. (2013). "Trends in childhood brain tumor incidence, 1973-2009". J Neurooncol. 115 (2): 153–60. doi:10.1007/s11060-013-1212-5. PMC 4056769. PMID 23925828.
  5. Bartlett F, Kortmann R, Saran F (2013). "Medulloblastoma". Clin Oncol (R Coll Radiol). 25 (1): 36–45. doi:10.1016/j.clon.2012.09.008. PMID 23245832.
  6. Leary SE, Olson JM (2012) The molecular classification of medulloblastoma: driving the next generation clinical trials. Curr Opin Pediatr 24 (1):33-9. DOI:10.1097/MOP.0b013e32834ec106 PMID: 22189395
  7. Roberts RO, Lynch CF, Jones MP, Hart MN (1991). "Medulloblastoma: a population-based study of 532 cases". J Neuropathol Exp Neurol. 50 (2): 134–44. PMID 2010773.

Template:WH Template:WS